Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data set.

Publication Type:

Journal Article


Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Volume 28, Issue 3, p.460-5 (2010)


2010, Antineoplastic Combined Chemotherapy Protocols, Center-Authored Paper, Chemotherapy, Adjuvant, Colonic Neoplasms, Disease-Free Survival, Follow-Up Studies, Humans, Neoplasm Recurrence, Local, Public Health Sciences Division, Survival Analysis, Time Factors


We previously validated disease-free survival (DFS) as a surrogate for overall survival (OS) in fluorouracil-based adjuvant colon cancer clinical trials. New therapies have extended survival after recurrence from 1 to approximately 2 years. We examined the possible impact of this improvement on the DFS/OS association.